Tag Archives: IL

1×4 or 1×6 copperwood fence installed with steel posts

By treen38

Hello!
A couple months ago I researched wood fencing and got estimates. I visited a fencing business to see a multi-year old comparison of cedar vs copperwood privacy fencing which were installed side-by-side with steel posts. Thought pickets(individual vert) were 1×6.
Yesterday I signed off to have work done. Estimator only gave me other addresses to see fencing yesterday. I noted contract was for 1×4 ‘pickets’. Note this does truly refer to 6′ tall privacy fence not a picket fence.
Questions:
*Is there a difference in durability between 1×4 and 1×6 6′ tall pickets (ie warping, twisting, etc)? Aesthetically, I prefer 1×6 but don’t know if this is actually an option.
*I know that steel posts allow the fence to have more ‘give’ & that use of wooden posts allows for a more rigid fence. They drive the Steel posts 4′ into the ground(I will dbl check this, otherwise 3′ but believe the former). No concrete is used with the steel posts. Is this acceptable? I live in IL. If I’d chosen treated wooden posts, they’d use concrete. BTW, they don’t use post caps on the wooden posts & other companies didn’t either. The company I chose is well-respected in the area.
*My 15yo Menards picket fence is spaced 8′ apart between wooden posts I set in concrete. I elected to continue the 8′ length with new fence but would 6′ spacing be better d/t use of steel posts already creating a less rigid fence? Is it possible to add a wooden post at corners and 1 in center of the (longest) 49′ run or would this put different stresses on opposite side of fence panels and create problems? (panels are not pre-fab. Fence built on-site)
BTW: 21’x49’x12′ footage + 2 gates. I asked that fence be level on the top and that fence pickets be 2″ off the ground. I currently have brick placed ground-level below my old fence to lessen trimming. Rales are 2×4. Any advice would be much appreciated! Thank-you.

…read more

Source: DoItYourself.com

Remarks by the President on the Economy — Knox College, Galesburg, IL

By The White House

Knox College
Galesburg, Illinois

12:13 P.M. CDT

THE PRESIDENT: Hello, Galesburg! (Applause.) Well, it’s good to be home in Illinois! (Applause.) It is good to be back. It’s good to be back. Thank you. Thank you so much, everybody. (Applause.) Thank you. Everybody, have a seat, have a seat. Well, it is good to be back.

I want to, first of all, thank Knox College — (applause) — I want to thank Knox College and your president, Teresa Amott, for having me here today. Give Teresa a big round of applause. (Applause.) I want to thank your Congresswoman, Cheri Bustos, who’s here. (Applause.) We've got Governor Quinn here. (Applause.) I'm told we've got your Lieutenant Governor, Sheila Simon, is here. (Applause.) There she is. Attorney General Lisa Madigan is here. (Applause.)

I see a bunch of my former colleagues, some folks who I haven't seen in years and I'm looking forward to saying hi to. One in particular I've got to mention, one of my favorites from the Illinois Senate — John Sullivan is in the house. (Applause.) John was one of my earliest supporters when I was running for the U.S. Senate, and it came in really handy because he’s got, like, 10 brothers and sisters, and his wife has got 10 brothers and sisters — (laughter) — so they’ve got this entire precinct just in their family. (Laughter.) And they all look like John — the brothers do — so he doesn’t have to go to every event. He can just send one of his brothers out. (Laughter.) It is good to see him.

Dick Durbin couldn’t make it today, but he sends his best. And we love Dick. (Applause.) He’s doing a great job. And we’ve got one of my favorite neighbors, the Senator from Missouri, Claire McCaskill, in the house, because we’re going to Missouri later this afternoon. (Applause.)

And all of you are here, and it’s great to see you. (Applause.) And I hope everybody is having a wonderful summer. The weather is perfect. Whoever was in charge of that, good job. (Laughter.)

So, eight years ago, I came here to deliver the commencement address for the class of 2005. Things were a little different back then. For example, I had no gray hair — (laughter) — or a motorcade. Didn’t even have a prompter. In fact, there was a problem in terms of printing out the speech because the printer didn’t work here and we had to drive it in from somewhere. (Laughter.) But it was my first big speech as your newest senator.

And on the way here I was telling Cheri and …read more

Source: FULL ARTICLE at The White House Press Office

White House Photographer Pete Souza Joins Instagram

By <a href="/author-detail/45">Kori Schulman</a>

Pete Souza, the Chief Official White House Photographer, is now on Instagram—and it's an account worth following. Through his Instagram account, you'll get a unique look at the presidency with behind-the-scenes photos from the road and around the White House.

Take a look at Pete's first day on Instagram (so far), as President Obama traveled to Knox College in Galesburg, IL to lay out his economic vision where everyone who works hard can get ahead. Then, head on over to Instagram to follow Pete Souza (and to check out our other official Instagram accounts for the White House and First Lady Michelle Obama).

For more photos from Pete Souza and the White House photo office, follow @PeteSouza on Twitter, and visit Flickr.com/WhiteHouse and WH.gov/photos.

read more

…read more

Source: FULL ARTICLE at The White House

Press Gaggle by Press Secretary Jay Carney aboard Air Force One en route to Galesburg, IL, 7/24/13

By The White House

Aboard Air Force One
En Route Galesburg, Illinois

11:16 A.M. EDT

MR. CARNEY: Welcome aboard Air Force One. It’s been a little bit since we've had the great honor and privilege of flying aboard this terrific airplane. We're headed, as you know, to Illinois, to Knox College in Galesburg, where the President will deliver a major economic address, laying out his vision for where we need to go in our economy to ensure that we have a rising and thriving middle class, because that is essential for the long-term health of our economy and for the American people.

So we've spoken a lot about that already this week. I wanted to let you know that later in the day when he travels to the University of Central Missouri, home to the Missouri Innovation Campus, he will note that the Missouri Innovation Campus prepares students with the education and skills they need to succeed at an accelerated pace while lowering costs and without student debt. Established in 2012, the Missouri Innovation Campus was developed through a partnership between the University of Central Missouri, Lee’s Summit School District, Metropolitan Community College, and local companies in order to drive growth in critical areas for the regional economy, including health care, engineering, energy and infrastructure.

The Missouri Innovation Campus provides an integrated academic experience that combines real-world, on-the-job experience with rigorous academics to graduate students from high school with a diploma as well as an associate’s degree, and then allowing them to earn a bachelor’s degree in only two years. This partnership provides students with a well-aligned education and prepares them with the skills they need to succeed in the Missouri economy and graduate with sought-after skills for high-paying careers, creating a pipeline for high school students to earn their diploma and degrees and get hired by local companies.

And I think it reflects the President’s firm belief that education is a cornerstone to the foundation we need to build economically. And that's why ensuring that as many Americans have access to higher education as possible and can afford that higher education is so important to the President.

With that, I will take your questions.

Q Jay, what is the latest information the White House has on the status of Edward Snowden? There were Russian media reports earlier today that he had gotten papers that would allow him to enter Russia, and then the latest update that we had was that his lawyer said that he was going to stay in the transit zone in the airport. So what’s the latest that you all know about him?

MR. CARNEY: Thank you, Darlene. We have seen reports of the nature you just described and of both kinds, and we are seeking clarity from Russian authorities about Mr. Snowden’s status and any change in it. But beyond that, I don't have any more information. And I can say that our position on Mr. Snowden remains what it …read more

Source: White House Press Office

Report: Chicago sinkhole swallows three cars, injures one person [w/video]

By Zach Bowman

Filed under: ,

Residents in Chicago’s south side had a scare after a 40-foot-wide sinkhole opened up at 96th and Houston this morning. Two cars were immediately consumed by the void and a third fell in shortly after firefighters arrived on the scene, according to The Huffington Post. One pedestrian also fell in and suffered mild injuries. Chicago has seen over five inches of rain fall in less than 24 hours, saturating the ground and causing extensive flooding.

Sinkholes typically form in areas with easily dissolved rocks underground, such as limestone. As groundwater erodes these rocks, voids form in the soil, and heavy rains can cause those voids to implode, bringing the surface down at the same time. The Jeffrey Manor neighborhood, where this sinkhole occurred, is just 15 miles from the Thornton Limestone Quarry in Thornton, IL. You can watch a local news report on the incident below for more information.

Continue reading Chicago sinkhole swallows three cars, injures one person [w/video]

Chicago sinkhole swallows three cars, injures one person [w/video] originally appeared on Autoblog on Thu, 18 Apr 2013 17:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

From: http://feeds.autoblog.com/~r/weblogsinc/autoblog/~3/Xgs50xoIm-g/

Advaxis to Report 12-Month Survival from Its Phase 2 Study of ADXS-HPV in Women with Recurrent/Refra

By Business Wirevia The Motley Fool

Filed under:

Advaxis to Report 12-Month Survival from Its Phase 2 Study of ADXS-HPV in Women with Recurrent/Refractory Cervical Cancer

-12-Month Survival Data From Phase 2 Study to Be Presented at 2013 ASCO Annual Meeting

-Two abstracts for ADXS-HPV, the Company’s lead drug candidate, have been selected for presentation at the 2013 American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J.–(BUSINESS WIRE)– Advaxis, Inc., (OTCBB: ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company’s lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 31 – June 4, 2013, at the McCormick Place Convention Center.

Abstract #5529, titled ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer, was selected for presentation at the Poster Discussion Session: Gynecologic Cancer to be held on June 2, 2013 from 8:00 – 11:30 a.m. This poster will describe updated safety, tumor response, and survival data from the ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin being conducted by Advaxis in India.

Abstract #TPS3121, titled A phase II study of live-attenuated Listeria monocytogenes immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265), was selected for presentation at the Developmental Therapeutics – ImmunotherapyTrials in Progress General Poster Session to be held on June 3, 2013 from 8:00 -11:45 a.m. This poster will describe the trial design for the ongoing Phase 2 study being conducted by the Gynecologic Oncology Group (GOG) in the United States.

Abstracts will be released on www.asco.org at 6:00 PM on May 15, 2013.

“We are pleased to have the opportunity to present the final 12-month survival and other relevant data from our 110 patient trial of ADXS-HPV in recurrent/refractory cervical cancer at ASCO‘s annual meeting,” commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. “ADXS-HPV immunotherapy offers the promise of an effective and well-tolerated treatment for cervical cancer that employs the patient’s immune system to fight the cancer. We are encouraged by the interest that our colleagues in GOG have in joining our efforts to evaluate the potential of ADXS-HPV in cervical cancer, through

From: http://www.dailyfinance.com/2013/04/17/advaxis-to-report-12-month-survival-from-its-phase/

OncoSec Medical to Present at the 2013 BIO International Convention on April 24

By Business Wirevia The Motley Fool

Filed under:

OncoSec Medical to Present at the 2013 BIO International Convention on April 24

SAN DIEGO–(BUSINESS WIRE)– OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present a company overview at the 2013 BIO International Convention. Mr. Dhillon’s presentation will take place on Wednesday, April 24, 2013 at 9:00 a.m. CT at the McCormick Place convention center in Chicago, IL.

About BIO International Convention 2013

BIO International Convention is the global event for the biotechnology industry attracting over 16,000 decision makers from 65 countries. The three-day event attracts thousands of companies from around the world and helps build strategic partnerships. BIO covers the wide spectrum of life science innovations and application areas. Drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy are just a few of the industries represented at the BIO International Convention.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical’s core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or

From: http://www.dailyfinance.com/2013/04/17/oncosec-medical-to-present-at-the-2013-bio-interna/

Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Au

By Business Wirevia The Motley Fool

Filed under:

Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases

ROCKVILLE, Md.–(BUSINESS WIRE)– Emergent BioSolutions Inc. (NYS: EBS) announced today that it has presented data on ES210, one of its bispecific ADAPTIRTM (Modular Protein Technology) molecules, that is targeting autoimmune disease at Keystone Symposia’s Advances in the Knowledge and Treatment of Autoimmunity in Whistler, British Columbia, Canada.

The ES210 molecule was engineered using Emergent’s ADAPTIR technology platform and contains binding sites specific for CD86 coupled to a monomeric form of IL-10 known to confer immunosuppressive activity.

The poster, entitled A Bispecific ADAPTIR™ Molecule That Targets CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a Therapeutic Treatment of Autoimmune Disease,”presentedpre-clinical data showing that ES210 displays high levels of in vitro and in vivo potency in blocking T-cell proliferation in human mixed lymphocyte reactions and in a humanized graft-versus-host disease model. Dendritic cells play a central role in the generation and regulation of immunity; therefore, targeting dendritic cell function represents a therapeutic opportunity to suppress immunopathological processes in autoimmune disease.

“Emergent is investigating an ADAPTIR molecule that targets and blocks the co-stimulatory receptor CD86, while delivering the immunosuppressive cytokine IL-10 to CD86-expressing antigen presenting cells,” said Jane Gross, Ph.D., vice president of applied research at Emergent BioSolutions. “We are pleased to present the study results, which show the ADAPTIR molecule as having potential applications in the treatment of transplant rejection as well as autoimmune and inflammatory diseases such as Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.”

About the ADAPTIR™ Platform

ADAPTIR bispecific proteins are modular, single chain polypeptides that comprise two separate binding domains (VL and VH), a hinge segment, and an effector domain (huFc). They have a differentiated structure from monoclonal antibodies and can generate a unique signaling response. In addition, ADAPTIR proteins may mediate complement dependent cytotoxicity and Fc dependent cytotoxicity, similar to monoclonal antibodies.

ADAPTIR is the new trademark for Emergent BioSolutions Inc.’s modular protein technologies that were previously identified using the SCORPIONTM (multispecific protein therapeutic) and SMIPTM (monospecific protein therapeutic) trademarks. ADAPTIR and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.

About Emergent

From: http://www.dailyfinance.com/2013/04/11/emergent-biosolutions-presents-efficacy-data-on-es/

PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Resp

By Business Wirevia The Motley Fool

Filed under:

PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor Types

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced details of a poster presentation on the induction of a systemic immune response with intralesional (IL) PV-10 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.

The poster entitled, “Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma,” was presented by Shari Pilon-Thomas, Ph.D., Immunology Program, Moffitt Cancer Center.

Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases (i.e., bystander lesions).

The Moffitt study examined the immunologic mechanism of PV-10 treatment in murine models of breast cancer and melanoma to determine how IL PV-10 therapy induces the systemic anti-tumor immune response apparent in bystander responses in clinical trial participants. In the current work, IL injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions in the MT-901 breast cancer model, with a significant increase in survival in mice treated with IL PV-10 versus those treated with IL saline. In a synchronous flank tumor/lung metastasis model, there was a significant reduction in lung metastases and subcutaneous tumor size in mice treated with IL PV-10 versus those treated with IL saline. Injection of PV-10 into the opposite, non-tumor bearing flank, did not affect the size of subcutaneous lesions nor the number of lung metastases. Splenocytes harvested from PV-10-treated mice exhibited tumor-specific enhancement of interferon-gamma production and cytotoxicity against the treated cell line, along with adoptive transfer of immunity upon implantation in naïve mice. A copy of the poster is available at the following link:

http://www.pvct.com/publications/SPTAACR2013-Final.pdf

Dr. Pilon-Thomas commented, “The findings of this study confirmed not only that PV-10 induces tumor-specific immunity after a single treatment with IL-PV-10 in multiple tumor types, but that the ablative process is critical for this in situ stimulation of the immune system. The data also show that T cells play a critical role in this response. We feel this is a promising direction for additional

Source: FULL ARTICLE at DailyFinance

Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annu

By Business Wirevia The Motley Fool

Filed under:

Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual Meeting

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.

The presentation, based upon Abstract #4755 entitled, “Combination of PV-10 Immuno-chemoablation and Systemic Anti-CTLA-4 Antibody Therapy in Murine Models of Melanoma,” was authored by Eric Wachter, Savannah Blair, Jamie Singer and Craig Dees, all of Provectus Pharmaceuticals. The poster was presented by Dr. Wachter, Chief Technology Officer.

PV-10 is Provectus Pharmaceuticals‘s novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Previous preclinical and clinical studies have established that upon intralesional (IL) administration, PV-10 localizes to injected tumor tissues while rapidly clearing from healthy tissue. Intralesional injection with PV-10 focuses the ablative impact on injected tumors and minimizes the potential for systemic side effects, making it an attractive candidate for both monotherapy and for combination therapy with other agents.

In Phase 2 testing PV-10 elicited an objective response rate of 51% in melanoma patients (CR: 25%; PR: 26%) after 1-4 treatment cycles, with a third of patients experiencing an objective response in their monitored untreated tumors (CR: 26%; PR: 7% in 42 patients with monitored untreated lesions). This apparent immune-mediated bystander response was highly correlated with successful ablation of injected tumors. Recent mechanism studies in B16 murine melanoma tumor lines have confirmed that PV-10 ablation induces T-cell mediated tumor-specific immunity, resulting in marked suppression of untreated metastases and tumor-specific IFN-ˠ production.

The data presented today at AACR utilized systemic immune stimulation by the anti-CTLA-4 antibody 9H10 to explore the potential benefit of combination therapy with PV-10 immuno-chemoablation in murine melanoma. Because advanced melanoma patients, particularly those with stage IV disease, have substantial tumor burden in areas that are often non-accessible to injection with PV-10, combination of PV-10 with systemic therapy may afford advantage in control of uninjected disease while the immunologic effects of PV-10 reach full potential. By combining PV-10 with the anti-CTLA-4 antibody 9H10 in very aggressive murine models of metastatic disease, researchers at Provectus aimed to ensure that any systemic treatment was potentially safe in combination with PV-10, and that efficacy signals from the combination therapy could be differentiated from those of PV-10 alone.

In order to discriminate the systemic effect of PV-10 alone from that in

Source: FULL ARTICLE at DailyFinance

PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for

By Business Wirevia The Motley Fool

Filed under:

PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that a poster presentation detailing the induction of tumor specific immunity after intralesional PV-10 treatment was presented by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.

The poster presentation, based on Abstract #1248 entitled, “Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma,” was authored by Shari Pilon-Thomas1, Amy Weber1, Krithika Kodumudi1, Lisa Kuhn1, Paul Toomey2 and Amod A. Sarnaik1 of 1Moffitt Cancer Center, Tampa, FL and the 2University of South Florida, Tampa, FL.

Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases.

The Moffitt Cancer Center investigational study, which examined the potential immune mechanism of PV-10 treatment in murine models of breast cancer and melanoma, demonstrated that injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions, with a significant increase in survival in mice treated with PV-10. In related experiments using a melanoma lung metastasis model, mice that received PV-10 treatment of a cutaneous tumor had markedly fewer lung metastases compared to controls receiving saline. The poster was presented by Shari Pilon-Thomas, Ph.D, Immunology Program, Moffitt Cancer Center.

Dr. Pilon-Thomas commented, “We believe our findings are meaningful because they confirm the induction of tumor-specific immunity after single treatment with ILPV-10 in multiple tumor types. Our data show that T cells play a crucial roll in this response, and we are continuing our work to further elucidate the mechanisms that occur following PV-10 treatment.”

Dr. Amod Sarnaik observed, “The systemic response to intralesional PV-10 treatment observed in murine models was sufficiently compelling to warrant further clinical investigation. We look forward to additional insights from our current investigational study of the immune mechanism of PV-10 ablation in cutaneous melanoma patients.”

Additional details on the immunological mechanism of action of PV-10 being presented during the AACR Annual Meeting poster session will be forthcoming. Abstract #1248 can be accessed at the following link:

…read more

Source: FULL ARTICLE at DailyFinance

Computational study of ionic liquids illuminates detailed CO2 interactions

Ionic liquids (ILs), which can be thought of as salts that are molten at room temperature, are being studied for use as part of CO2 adsorption and/or separation technologies. These applications depend on having strong interactions between the CO2 and the ions of the IL. In order for significant advances to occur in this area of research, the interaction between the CO2 and each IL must be understood and described with accuracy. Computational methods are used to describe these interactions on a molecular level. …read more
Source: FULL ARTICLE at Phys.org

Atlas Announces 2013 Annual Meeting of Shareholders

By Business Wirevia The Motley Fool

Filed under:


Atlas Announces 2013 Annual Meeting of Shareholders

CHICAGO–(BUSINESS WIRE)– Atlas Financial Holdings, Inc. (NASDAQ: AFH; TSX.V: AFH) (“Atlas” or the “Company”) announced today that the Company’s Board of Directors has called an Annual General Meeting of shareholders to be held on May 30, 2013 at 10:00 am central time, at the Company’s headquarters at 150 Northwest Point Boulevard, Elk Grove Village, IL 60007. A record date of April 26, 2013 has been set for determining shareholders entitled to receive notice of the meeting. Details of, and the agenda for, the meeting will be set forth in the Company’s management information circular to be mailed to shareholders.

About Atlas

The primary business of Atlas is commercial automobile insurance in the United States, with a niche market orientation and focus on insurance for the “light” commercial automobile sector including taxi cabs, non-emergency paratransit, limousine/livery and business auto. The business of Atlas is carried on through its insurance subsidiaries American Country Insurance Company, American Service Insurance Company, Inc. and Gateway Insurance Company. Atlas’ insurance subsidiaries have decades of experience with a commitment to always being an industry leader in these specialized areas of insurance.

For more information about Atlas, please visit www.atlas-fin.com.

Financial Information

Atlas’ financial statements reflect consolidated results of Atlas’ subsidiaries: American Insurance Acquisition Inc., American Country Insurance Company and American Service Insurance Company, Inc. Additional information about Atlas, including a copy of Atlas’ 2012 Form 10-K financial statements and Management Discussion & Analysis, can be accessed on the Canadian Securities Administrators‘ website at www.sedar.com, via the U.S. Securities and Exchange Commission internet site at www.sec.gov or through Atlas’ website at www.atlas-fin.com.

Forward-Looking Statements:

This release includes forward-looking statements regarding Atlas and its insurance subsidiaries and businesses. Such statements are based on the current expectations of the management of each entity. The words “anticipate”, “expect”, “believe”, “may”, “should”, “estimate”, “project”, “outlook”, “forecast” or similar words are used to identify such forward looking information. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known …read more
Source: FULL ARTICLE at DailyFinance

InnerWorkings Earns Recognition as a John Deere "Partner-level Supplier"

By Business Wirevia The Motley Fool

Filed under:

InnerWorkings Earns Recognition as a John Deere “Partner-level Supplier”

Company Named to Supplier Hall of Fame

CHICAGO–(BUSINESS WIRE)– InnerWorkings (NASDAQ: INWK), a leading global marketing supply chain company, today announced that it has earned recognition as a Partner-level supplier for 2012 and was inducted into the Supplier Hall of Fame in the John Deere Achieving Excellence Program. Hall of Fame status is given after a supplier attains a Partner-level rating for five consecutive years. The Partner-level status is Deere & Company’s highest supplier rating. The Chicago-based company was selected for the honor in recognition of its dedication to providing products and services of outstanding quality as well as its commitment to continuous improvement. Company employees accepted the recognition during formal ceremonies held on March 5 in Davenport, Iowa.

InnerWorkings is the print management solutions provider for John Deere‘s operations in North America.

“Receiving this recognition from Deere & Company and being inducted into the Hall of Fame shows the strength of InnerWorkings’ solution to deliver exceptional print management services to our clients,” said John Eisel, chief operating officer of InnerWorkings. “Deere & Company expects outstanding performance from its partners and the dedication of our team is evidenced by achieving this award for the fifth consecutive year.”

Suppliers who participate in the Achieving Excellence program are evaluated annually in several key performance categories, including quality, cost management, delivery, technical support and wavelength, which is a measure of responsiveness. John Deere Supply Management created the program in 1991 to provide a supplier evaluation and feedback process that promotes continuous improvement.

About InnerWorkings, Inc.

InnerWorkings, Inc. (NAS: INWK) is a leading global marketing supply chain company servicing corporate clients across a wide range of industries. With proprietary technology, an extensive supplier network and deep domain expertise, the Company procures, manages and delivers printed materials and promotional products as part of a comprehensive outsourced enterprise solution. InnerWorkings is based in Chicago, IL, employs approximately 1,300 individuals, and maintains 47 global offices. Among the many industries InnerWorkings services are: retail, financial services, hospitality, non-profits, healthcare, food & beverage, broadcasting & cable, education, transportation and utilities.

For more information visit: www.inwk.com.

…read more
Source: FULL ARTICLE at DailyFinance

Chairman and CEO Thomas Motamed Welcomed More Than 40 Agents to CNA's First-Ever Technology Cloud Sc

By Business Wirevia The Motley Fool

Filed under:

Chairman and CEO Thomas Motamed Welcomed More Than 40 Agents to CNA’s First-Ever Technology Cloud School

CHICAGO–(BUSINESS WIRE)– Thomas F. Motamed, Chairman and Chief Executive Officer of CNA, yesterday welcomed more than 40 agents and brokers to the company’s first-ever Technology Cloud School , a half-day session designed to provide better insight into managing the risks of cloud computing.

“Technology is changing the way business gets done. Tools that connect businesses to their customers and suppliers are making us more efficient and more responsive. But these tools are also creating exposures to complex risks that didn’t exist a few years ago,” said Motamed during his welcoming remarks at the CNA Corporate Headquarters, 333 South Wabash, Chicago, IL.

“Working together, we need to understand this complexity, as well as the options for managing the inherent risks. And that’s what we are here to accomplish,” he added.

Professionals from CNA Information Technology (IT), Underwriting, Claim and Risk Control came together to facilitate the Cloud School. The agenda included examining trends in the enterprise software environment, discussing increased risks related to security, privacy and interruption of IT services, and exploring best practices for assessing and managing these risks in enterprise software vendor relationships.

This was the first of several Technology Cloud Schools that CNA will be hosting in cities throughout the United States in 2013 and 2014.

For more information on the CNA Technology Cloud School, contact Valynda Murphy at 312-822-2821 or at valynda.murphy@cna.com

Serving businesses and professionals since 1897, CNA is the country’s seventh largest commercial insurance writer and the 13th largest property and casualty company. CNA‘s insurance products include standard commercial lines, specialty lines, surety, marine and other property and casualty coverages. CNA‘s services include risk management, information services, underwriting, risk control and claims administration. For more information, please visit CNA at www.cna.com.”CNA” is a service mark registered by CNA Financial Corporation with the United States Patent and Trademark Office. Certain CNA Financial Corporation subsidiaries use the “CNA” service mark in connection with insurance underwriting and claims activities.

Follow CNA on: Facebook | Twitter

CNA
Jennifer Martinez, 312-822-5167
or
Sarah Pang, 312-822-6394

KEYWORDS:   United States  North America  Illinois

INDUSTRY KEYWORDS:

The article Chairman and CEO Thomas Motamed Welcomed More Than 40 Agents to …read more
Source: FULL ARTICLE at DailyFinance

Hagens Berman Investigates Great Lakes Dredge &amp; Dock Corporation Following COO Resignation and Finan

By Business Wirevia The Motley Fool

Filed under:

Hagens Berman Investigates Great Lakes Dredge & Dock Corporation Following COO Resignation and Financials Restatement

CHICAGO–(BUSINESS WIRE)– Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm with an office in Chicago, IL, today announced it is investigating Great Lakes Dredge & Dock Corp. (NAS: GLDD) (“GLDD” or “the company”) following the resignation of the company’s Chief Operating Officer and President Bruce J. Biemeck, a restatement of the company’s financial statements and a subsequent 30 percent drop in the company’s stock price in after-hours trading.

If you purchased shares of GLDD common stock between August 7, 2012, and March 14, 2013, inclusive (the “class period”), suffered significant losses and wish to move to be a lead plaintiff, you may contact Hagens Berman Partner Reed Kathrein, who is leading the Firm’s investigation, by calling 510-725-3000 or emailing GLDD@hbsslaw.com.

The Firm’s investigation centers around GLDD‘s restatement of financial results, issued just after close of trading on March 14, 2013. The company stated that for the second and third financial quarters of 2012, “Certain pending change orders where client acceptance has not been finalized were included as revenue. After a review, the Company concluded 2012 second and third quarter demolition segment revenues were overstated by $3.9 million and $4.3 million, respectively.”

The announcement coincided with the company’s disclosure that Bruce J. Biemeck, the company’s President, COO and former Chief Financial Officer, is departing the company.

Hagens Berman is investigating whether the company knew and failed to disclose material information to investors, particularly revenue issues in the second and third financial quarters of 2012, and thus is responsible for investor losses. Following the company’s restatement, GLDD‘s stock price fell by more than 30 percent in after-hours trading on March 14, 2013.

“The company has effectively admitted that, in violation of its established policies, it counted revenue that should have not been counted,” said Mr. Kathrein. “Taken together with the resignation of Mr. Biemeck, we are concerned that the company and certain of its officers may have known about or even been knowingly complicit in the misstatement, to the detriment of investors who lacked this information.”

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

…read more
Source: FULL ARTICLE at DailyFinance

Globus Medical to Present at the Canaccord Genuity Musculoskeletal Conference

By Business Wirevia The Motley Fool

Filed under:

Globus Medical to Present at the Canaccord Genuity Musculoskeletal Conference

AUDUBON, Pa.–(BUSINESS WIRE)– Globus Medical, Inc. (NYS: GMED) , a leading spinal implant manufacturer, today announced that Dave Demski, President and Chief Operating Officer, and Richard Baron, Senior Vice President and Chief Financial Officer, will present at the 2013 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19, 2013 at 2:30 p.m. ET (1:30 PM CT) at the Westin Michigan Avenue, in Chicago, IL.

Interested institutional investors that wish to schedule a meeting should contact Canaccord Genuity.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading spinal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of spine professionals with a shared vision to create products that enable spine surgeons to promote healing in patients with spinal disorders. Additional information can be accessed at www.globusmedical.com.

Globus Medical, Inc.
Ed Joyce, 610-930-1800
investors@globusmedical.com
www.globusmedical.com

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

The article Globus Medical to Present at the Canaccord Genuity Musculoskeletal Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
…read more
Source: FULL ARTICLE at DailyFinance

InnerWorkings to Present at Sidoti Emerging Growth Forum

By Business Wirevia The Motley Fool

Filed under:

InnerWorkings to Present at Sidoti Emerging Growth Forum

CHICAGO–(BUSINESS WIRE)– InnerWorkings (NASDAQ: INWK), a leading global marketing supply chain company announced that Chief Financial Officer, Joseph Busky, will present at the Sidoti Emerging Growth Forum in New York on Tuesday, March 19, 2013.

A live webcast of the Company’s presentation, which begins Tuesday, March 19th at 1:20 p.m. Eastern Time, can be accessed by visiting the “Events & Presentations” section of the InnerWorkings website at http://investor.inwk.com/events.cfm. A replay of the webcast will be available for 90 days after the presentation and can be accessed at the same web address.

About InnerWorkings, Inc.

InnerWorkings, Inc. (NAS: INWK) is a leading global marketing supply chain company servicing corporate clients across a wide range of industries. With proprietary technology, an extensive supplier network and deep domain expertise, the Company procures, manages and delivers printed materials and promotional products as part of a comprehensive outsourced enterprise solution. InnerWorkings is based in Chicago, IL, employs approximately 1,300 individuals, and maintains 44 global offices. Among the many industries InnerWorkings services are: retail, financial services, hospitality, non-profits, healthcare, food & beverage, broadcasting & cable, education, transportation and utilities.

For more information visit: www.inwk.com.

InnerWorkings, Inc.
Brad Moore, (312) 277-1510
bmoore@inwk.com

KEYWORDS:   United States  North America  Illinois  New York

INDUSTRY KEYWORDS:

The article InnerWorkings to Present at Sidoti Emerging Growth Forum originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

…read more
Source: FULL ARTICLE at DailyFinance

WageWorks Announces Pricing of its Follow-On Public Offering

By Business Wirevia The Motley Fool

Filed under:

WageWorks Announces Pricing of its Follow-On Public Offering

SAN MATEO, Calif.–(BUSINESS WIRE)– WageWorks, Inc. (NYS: WAGE) today announced the pricing of its follow-on public offering of 5,631,115 shares of its common stock at a price to the public of $24.00 per share. WageWorks is selling 500,000 shares of common stock in this offering, and selling stockholders are selling 5,131,115 shares of common stock in this offering. The underwriters have an option to purchase a maximum of 844,667 additional shares from the selling stockholders identified in the prospectus for this offering to cover overallotments, if any.

WageWorks will not receive any proceeds from the sale of shares to be offered by the selling stockholders. The principal purposes of this offering are to facilitate an orderly distribution of shares for the selling stockholders, to increase the public float and to raise additional capital. The proceeds of the primary portion of the offering will be used to provide additional working capital for WageWorks and general corporate purposes, including further expansion of sales and marketing efforts, continued investments in technology and development and for capital expenditures.

William Blair & Company, L.L.C. and Stifel, Nicolaus & Company, Incorporated are serving as joint book-running managers for the offering, with JMP Securities LLC and Needham & Company, LLC, acting as co-managers.

A registration statement relating to shares of the common stock of WageWorks has been declared effective by the Securities and Exchange Commission. This offering is being made by WageWorks and the selling stockholders only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus for the offering may be obtained from William Blair & Company, L.L.C. at 222 West Adams Street, Attention: Prospectus Department, Chicago, IL 60606, phone number (800) 621-0687, or from Stifel, Nicolaus & Company, Incorporated at One Montgomery Street, Suite 3700, San Francisco, California 94104, phone number (415) 364-2720.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor Relations:
ICR
Staci Mortenson, 650-577-6300
ir@wageworks.com
or
Media:
WageWorks, Inc.
Britta …read more
Source: FULL ARTICLE at DailyFinance

Orthofix to Participate in the Canaccord Genuity Musculoskeletal Conference

By Business Wirevia The Motley Fool

Filed under:

Orthofix to Participate in the Canaccord Genuity Musculoskeletal Conference

LEWISVILLE, Texas–(BUSINESS WIRE)– Orthofix International N.V., (NAS: OFIX) (the Company) announced today that it will be participating in the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19th at 8:50 a.m. Central Time at The Westin Michigan Avenue in Chicago, IL.

A live audio webcast will be available on the Company’s website at www.orthofix.com by clicking on the Investors tab and then clicking the link on the Events & Presentations page.


About Orthofix:

Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix’s products are widely distributed around the world to surgeons and patients via Orthofix’s sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.

Orthofix International N.V.
Mark Quick, 214-937-2924
Director of Investor Relations and Business Development
markquick@orthofix.com

KEYWORDS:   United States  North America  Illinois  Texas

INDUSTRY KEYWORDS:

The article Orthofix to Participate in the Canaccord Genuity Musculoskeletal Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
…read more
Source: FULL ARTICLE at DailyFinance